The ALS Association

Ice Bucket Challenge Progress

Sanofi Sells Rilutek to Covis Pharma Sarl

April 4, 2013

Today, Covis Pharma Sarl, a Switzerland-based specialty pharmaceutical company, announced its agreement with sanofi-aventis U.S. LLC to acquire rights to Rilutek® (riluzole), which is an approved drug by the U.S. Food and Drug Administration (FDA) to treat ALS. Other compounds were also included in this aggregate sale. This international company has a U.S. affiliate, Covis Pharmaceuticals, in Cary, North Carolina.

More information on the sale of Rilutek can be found here.

Powered by Blackbaud
nonprofit software